Surgery, Gastroenterology and Oncology
Vol. 25, No. 3, June 2020
Factors Impacting Survival Outcomes after Curative Resection for Primary Duodenal Adenocarcinoma
Masayuki Urabe, Junichi Shindoh, Yuta Kobayashi, Satoshi Okubo, Shusuke Haruta, Masaki Ueno, Masaji Hashimoto
ORIGINAL PAPER, June 2020
Article DOI: 10.21614/sgo-25-3-132
Background: Primary duodenal adenocarcinoma (PDA) is a rare gastrointestinal tumor and factors predicting survival outcomes after curative resection have yet to be fully elucidated.

Methods: Applying the Cox proportional hazard model, we retrospectively evaluated associations between overall relapse-free survivals (OS RFS) and 18 clinicopathological factors in 33 patients who had undergone R0 resection for PDA.

Results: Univariate analysis revealed worsening RFS to be significantly related to pancreatic invasion, multiple nodal metastases, and the preoperative serum carcinoembryonic antigen level. Pancreatic invasion and multiple nodal metastases were also found to be significantly associated with poorer OS in the univariate analysis. In multivariate analysis, only pancreatic invasion was an independent predictor of OS (hazard ratio [HR] 5.27, 95% confidence interval [CI] 1.15-24.2, P = 0.033). As to RFS, both pancreatic invasion and multiple nodal metastases correlated independently with unfavorable outcomes (HR 42.8, 95% CI 3.59 - 510, P = 0.003; HR 216, 95% CI 6.86 - 6.8 x 103, P = 0.002; respectively).
Only one of the 19 patients with PDA limited to the mucosal submucosal layer developed recurrent disease (local site), while seven patients with pancreatic invasion and or multiple nodal metastases all experienced meta chronous distant recurrence.

Conclusion: While the likelihood of progression to systemic disease after meticulous surgical removal is very low in early-stage PDA, patients with PDA invading the pancreas and or metastasizing to multiple lymph nodes are at high risk of developing distant relapse and may benefit from additional systemic therapy.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 3349


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.